As of November 14, 2026, Beam Therapeutics Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 5, 2026 (Form 8-K, February 5, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Beam Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Beam Therapeutics Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-05. Every row below is cited to the filing it comes from, and this page adds each new change as Beam Therapeutics Inc. files it.
Also on the record for Beam Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 13, 2026 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 11.43% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 9.95% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Farallon Capital Management, L.L.C. | 9.99% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.02% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.2% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by Dapice Joshua J. | 9.99% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 12.6% of the class | 5%+ stakes | Source |
| February 3, 2026 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 12.29% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 13.6% of the class | 5%+ stakes | Source |
| August 7, 2025 | Stake report, Schedule 13G/A, by ARK Investment Management LLC | 10.35% of the class | 5%+ stakes | Source |
| August 6, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 15% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Beam Therapeutics Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Beam Therapeutics Inc. and the records around it.
Beam Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Farallon Capital Management, L.L.C. also filed stake reports on 19 other companies: Avalo Therapeutics, Inc. (Nov 2026), BridgeBio Pharma, Inc. (Nov 2026), Crinetics Pharmaceuticals, Inc. (Nov 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)
- ARK Investment Management LLC also filed stake reports on 23 other companies: CERUS CORP (Nov 2026), CRISPR Therapeutics AG (Nov 2026), GeneDx Holdings Corp. (Nov 2026)
Watch Beam Therapeutics Inc.
Get an email when Beam Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Beam Therapeutics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Beam Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Beam Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-05 | Reported | not named in the filing | 8-K, 2026-02-05 |
New leaders reset buying decisions — get the Full Report on Beam Therapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Beam Therapeutics Inc., with the record behind each one.
Find candidates like senior executive at Beam Therapeutics Inc.Every change, in the filing's words
Reported
On January 31, 2026, Carole Ho provided Beam Therapeutics Inc. (the "Company") with notice of her resignation from the Board of Directors of the Company, effective as of February 27, 2026.
- Dr. Ho's decision to resign did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Tools for this story
Each opens in a new tab, filled in for Beam Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
